The goal of this observational study is to investigate the correlation and quantitative relationship between the analgesic effect of fentanyl transdermal patches in cancer pain patients and their nutritional status.
Cancer-related pain is one of the most common and unbearable symptoms among patients with malignant tumors. Opioids are commonly used to treat moderate or severe cancer pain. Among them, fentanyl is a synthetic opioid with analgesic adjuvant with a 50\~100 times higher potency than morphine. Due to its small molecular weight, high lipid solubility, and low irritation to the skin, transdermal fentanyl (TDF) is formulated, which is more convenient for patients with intestinal obstruction, swallowing difficulties, and intolerance to oral opioids. According to some research, the TDF demonstrated good cancer pain control for patients switching from morphine or oral oxycodone preparations, and was well tolerated. However, a part of patients still go through increased breakthrough pain, sleep disturbances, and even accompanied by anxiety and depression when using TDF. Therefore, early identification of cancer pain patients using TDF at risk of ineffectiveness is an essential step in increasing analgesic effectiveness, and improving quality of life. Some studies discovered different clinical factors such as age, gender, serum albumin, glomerular filtration rate, kidney disease, body mass index (BMI), total protein, alanine aminotransferases have some influence on fentanyl serum concentration and the dose of TDF. Furthermore, the clinical factors seem to have a greater impact on the effectiveness of TDF than the genetic factors which may affect the liver metabolism of fentanyl. Based on these results, we aim to investigate the correlation and quantitative relationship between the analgesic effect of fentanyl transdermal patches in cancer pain patients and their nutritional status. Our purpose is to help clinicians recognize and increase the analgesic effect of TDF according to the patient's risk level.
Study Type
OBSERVATIONAL
Enrollment
151
Adult cancer pain patients switched from oral opioid to TDF
Chao Li
Chongqing, China
11-point numeric rating scale (NRS) after TDF treatment
Ineffectiveness defined as pain with a NRS of 4 or higher.
Time frame: in 1 week
the occasions that breakthrough pain attacks per day after TDF treatment
Ineffectiveness defined as the breakthrough pain attacks more than 3 occasions per day
Time frame: in 1 week
The dose adjustment of TDF
Ineffectiveness defined as the dosage of TDF increased
Time frame: in 1 week
The kinds of other analgesics combined with TDF
Ineffectiveness defined as more than one kind of analgesics were combined with TDF
Time frame: in 1 week
Adverse effects
Nausea, vomiting, dizziness, rash, constipation, urinary retention, respiratory depression
Time frame: in 1 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.